OBJECTIVE: In this article we focus on the role that chemokines and chemokine receptors play in the pathogenesis of multiple myeloma and the associated bone destructive process, and consider their utility as novel therapeutic targets for treating this devastating disease. METHODS: Current research on the role that chemokine and chemokine receptors play in the pathogenesis of myeloma is reviewed. RESULTS: The chemokines, MIP-1alpha, MCP-1, IL-8, and SDF-1, and their receptors play important roles in homing of MM cells, tumor growth, and bone destruction in myeloma. They are attractive therapeutic targets for treating myeloma patients. CONCLUSION: Addition of chemokine antagonists to current treatment regimens for myeloma should result in better therapeutic responses because of the loss of both the protective effect of the marrow microenvironment on the MM cells and the induction of osteoclast activity.
OBJECTIVE: In this article we focus on the role that chemokines and chemokine receptors play in the pathogenesis of multiple myeloma and the associated bone destructive process, and consider their utility as novel therapeutic targets for treating this devastating disease. METHODS: Current research on the role that chemokine and chemokine receptors play in the pathogenesis of myeloma is reviewed. RESULTS: The chemokines, MIP-1alpha, MCP-1, IL-8, and SDF-1, and their receptors play important roles in homing of MM cells, tumor growth, and bone destruction in myeloma. They are attractive therapeutic targets for treating myelomapatients. CONCLUSION: Addition of chemokine antagonists to current treatment regimens for myeloma should result in better therapeutic responses because of the loss of both the protective effect of the marrow microenvironment on the MM cells and the induction of osteoclast activity.
Authors: Kenneth C Anderson; John D Shaughnessy; Bart Barlogie; Jean-Luc Harousseau; G David Roodman Journal: Hematology Am Soc Hematol Educ Program Date: 2002
Authors: B K Arendt; A Velazquez-Dones; R C Tschumper; K G Howell; S M Ansell; T E Witzig; D F Jelinek Journal: Leukemia Date: 2002-10 Impact factor: 11.528
Authors: Manali S Bendre; Dana Gaddy-Kurten; Thetsu Mon-Foote; Nisreen S Akel; Robert A Skinner; Richard W Nicholas; Larry J Suva Journal: Cancer Res Date: 2002-10-01 Impact factor: 12.701
Authors: Khatora S Opperman; Kate Vandyke; Peter J Psaltis; Jacqueline E Noll; Andrew C W Zannettino Journal: Cancer Metastasis Rev Date: 2021-01-06 Impact factor: 9.264
Authors: Constantina A Pappa; George Tsirakis; Anna Boula; Aikaterini Sfiridaki; Fotios E Psarakis; Michael G Alexandrakis; Efstathios N Stathopoulos Journal: Pathol Oncol Res Date: 2013-02-28 Impact factor: 3.201
Authors: Rhamy Zeid; Matthew A Lawlor; Evon Poon; Jaime M Reyes; Mariateresa Fulciniti; Michael A Lopez; Thomas G Scott; Behnam Nabet; Michael A Erb; Georg E Winter; Zoe Jacobson; Donald R Polaski; Kristen L Karlin; Rachel A Hirsch; Nikhil P Munshi; Thomas F Westbrook; Louis Chesler; Charles Y Lin; James E Bradner Journal: Nat Genet Date: 2018-01-29 Impact factor: 38.330